BACKGROUND AND PURPOSE: Cannabidiol is a Cannabis-derived non-psychotropic compound that exerts a plethora of pharmacological actions, including anti-inflammatory, neuroprotective and antitumour effects, with potential therapeutic interest. However, the actions of cannabidiol in the digestive tract are largely unexplored. In the present study, we investigated the effect of cannabidiol on intestinal motility in normal (control) mice and in mice with intestinal inflammation. EXPERIMENTAL APPROACH: Motility in vivo was measured by evaluating the distribution of an orally administered fluorescent marker along the small intestine; intestinal inflammation was induced by the irritant croton oil; contractility in vitro was evaluated by stimulating the isolated ileum, in an organ bath, with ACh. KEY RESULTS: In vivo, cannabidiol did not affect motility in control mice, but normalized croton oil-induced hypermotility. The inhibitory effect of cannabidiol was counteracted by the cannabinoid CB1 receptor antagonist rimonabant, but not by the cannabinoid CB2 receptor antagonist SR144528 (N-[-1S-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide), by the opioid receptor antagonist naloxone or by the alpha2-adrenergic antagonist yohimbine. Cannabidiol did not reduce motility in animals treated with the fatty acid amide hydrolase (FAAH) inhibitor N-arachidonoyl-5-hydroxytryptamine, whereas loperamide was still effective. In vitro, cannabidiol inhibited ACh-induced contractions in the isolated ileum from both control and croton oil-treated mice. CONCLUSIONS AND IMPLICATIONS: Cannabidiol selectively reduces croton oil-induced hypermotility in mice in vivo and this effect involves cannabinoid CB1 receptors and FAAH. In view of its low toxicity in humans, cannabidiol may represent a good candidate to normalize motility in patients with inflammatory bowel disease.
BACKGROUND AND PURPOSE:Cannabidiol is a Cannabis-derived non-psychotropic compound that exerts a plethora of pharmacological actions, including anti-inflammatory, neuroprotective and antitumour effects, with potential therapeutic interest. However, the actions of cannabidiol in the digestive tract are largely unexplored. In the present study, we investigated the effect of cannabidiol on intestinal motility in normal (control) mice and in mice with intestinal inflammation. EXPERIMENTAL APPROACH: Motility in vivo was measured by evaluating the distribution of an orally administered fluorescent marker along the small intestine; intestinal inflammation was induced by the irritant croton oil; contractility in vitro was evaluated by stimulating the isolated ileum, in an organ bath, with ACh. KEY RESULTS: In vivo, cannabidiol did not affect motility in control mice, but normalized croton oil-induced hypermotility. The inhibitory effect of cannabidiol was counteracted by the cannabinoid CB1 receptor antagonist rimonabant, but not by the cannabinoid CB2 receptor antagonist SR144528 (N-[-1S-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide), by the opioid receptor antagonist naloxone or by the alpha2-adrenergic antagonist yohimbine. Cannabidiol did not reduce motility in animals treated with the fatty acid amide hydrolase (FAAH) inhibitor N-arachidonoyl-5-hydroxytryptamine, whereas loperamide was still effective. In vitro, cannabidiol inhibited ACh-induced contractions in the isolated ileum from both control and croton oil-treated mice. CONCLUSIONS AND IMPLICATIONS: Cannabidiol selectively reduces croton oil-induced hypermotility in mice in vivo and this effect involves cannabinoid CB1 receptors and FAAH. In view of its low toxicity in humans, cannabidiol may represent a good candidate to normalize motility in patients with inflammatory bowel disease.
Authors: Mauro A M Carai; Giancarlo Colombo; Gian Luigi Gessa; Ratnakumar Yalamanchili; Balapal S Basavarajappa; Balapal S Basavarajppa; Basalingappa L Hungund Journal: Br J Pharmacol Date: 2006-07-17 Impact factor: 8.739
Authors: R Capasso; F Borrelli; F Capasso; D J Siebert; D J Stewart; J K Zjawiony; A A Izzo Journal: Neurogastroenterol Motil Date: 2006-01 Impact factor: 3.598
Authors: Fabrício A Moreira; Daniele C Aguiar; Francisco S Guimarães Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2006-07-31 Impact factor: 5.067
Authors: M Bashashati; M A Storr; S P Nikas; J T Wood; G Godlewski; J Liu; W Ho; C M Keenan; H Zhang; S O Alapafuja; B F Cravatt; B Lutz; K Mackie; G Kunos; K D Patel; A Makriyannis; J S Davison; K A Sharkey Journal: Br J Pharmacol Date: 2012-03 Impact factor: 8.739
Authors: Susanne A Wolf; Anika Bick-Sander; Klaus Fabel; Perla Leal-Galicia; Svantje Tauber; Gerardo Ramirez-Rodriguez; Anke Müller; Andre Melnik; Tim P Waltinger; Oliver Ullrich; Gerd Kempermann Journal: Cell Commun Signal Date: 2010-06-17 Impact factor: 5.712
Authors: R Capasso; F Borrelli; M G Cascio; G Aviello; K Huben; J K Zjawiony; P Marini; B Romano; V Di Marzo; F Capasso; A A Izzo Journal: Br J Pharmacol Date: 2008-07-14 Impact factor: 8.739